|本期目录/Table of Contents|

[1]杨蕊旭,范建高.非酒精性脂肪性肝病的流行特征[J].传染病信息,2018,02:101-104,111.
 YANG Rui-xu,FAN Jian-gao*.Epidemiological features of non-alcoholic fatty liver diseases[J].Infectious Disease Information,2018,02:101-104,111.
点击复制

非酒精性脂肪性肝病的流行特征(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年02期
页码:
101-104,111
栏目:
导向与述评
出版日期:
2018-03-20

文章信息/Info

Title:
Epidemiological features of non-alcoholic fatty liver diseases
作者:
杨蕊旭范建高
200092,上海交通大学医学院附属新华医院消化 内科暨脂肪肝诊治中心(杨蕊旭、范建高)
Author(s):
YANG Rui-xu FAN Jian-gao*
Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200092, China
关键词:
非酒精性脂肪性肝病流行病学肥胖危险因素
Keywords:
non-alcoholic fatty liver disease epidemiology obesity risk factors
分类号:
R575
DOI:
10.3969/j.issn.1007-8134.2018.02.002
文献标识码:
A
摘要:
目前非酒精性脂肪性肝病已成为全球最主要的慢性肝病,其患病率在不同人种、国家、区域之间均有差异。 非酒精性脂肪性肝病的发病与肥胖、代谢综合征、生活方式、遗传、肌肉减少症等因素相关。目前亚洲地区非酒精性脂 肪性肝病的患病率与西方国家基本持平,但其流行病学特征与西方国家仍有差异。在亚洲,非肥胖型非酒精性脂肪性肝 病患者较西方更多,其发病多与遗传因素相关。慢性乙型肝炎合并脂肪性肝病患者数目较多,亦是亚洲地区的流行病学 特征。
Abstract:
Non-alcoholic fatty liver disease has been regarded as the predominant chronic liver disease worldwide and its prevalence varies from different ethics, countries and districts. The risk factors of non-alcoholic fatty liver disease include obesity, metabolic syndrome, lifestyle, genetic factor and sarcopenia. At present, the prevalence of non-alcoholic fatty liver disease in Asia is similar to that of western countries, but the epidemiological characteristics are still different from those in western countries. The non-obese non-alcoholic fatty liver disease is highly prevalent in Asia than in the western countries, and the incidence is related to genetic factors. Chronic hepatitis B concomitant of fatty liver is also an epidemiological feature of non-alcoholic fatty liver disease in Asia.

参考文献/References

[1] Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377(21):2063-2072.
[2] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84.
[3] Li Z, Xue J, Chen P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies [J]. J Gastroenterol Hepatol, 2014, 29(1):42-51.
[4] Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China[J]. J Hepatol, 2005, 43(3):508-514.
[5] Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China[J]. World J Gastroenterol, 2007, 13(47):6419-6424.
[6] Li H, Wang YJ, Tan K, et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China[J]. Hepatobiliary Pancreat Dis Int, 2009, 8(4):377-382.
[7] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67(4):862-873.
[8] Wei JL, Leung JC, Loong TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy[J]. Am J Gastroenterol, 2015, 110(9):1306-1314.
[9] Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults[J]. J Clin Gastroenterol, 2006, 40(8):745-752.
[10] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1):11-20.
[11] Garcia-Monzon C, Vargas-Castrillon J, Porrero JL, et al. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones[J]. Liver Int, 2015, 35(8):1983-1991.
[12] Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the dionysos stud[y J]. Hepatology, 2007, 46(5):1387-1391.
[13] 范建高,周琪,沃千红. 人体质量指数及其变化与非酒精 性脂肪性肝病发病的关系[J]. 中华肝脏病杂志,2010, 18(9):676-679.
[14] Zhou YJ, Li YY, Nie YQ, et al. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study[J]. J Dig Dis, 2012, 13(3):153-160.
[15] Xu C, Yu C, Ma H, et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai study[J]. Am J Gastroenterol, 2013, 108(8):1299-1304.
[16] Wong VW, Wong GL, Yeung DK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy[J]. J Hepatol, 2015, 62(1):182-189.
[17] Ryu S, Chang Y, Jung HS, et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease[J]. J Hepatol, 2015, 63(5):1229-1237.
[18] Li Y, Xing C, Cohen JC, et al. Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China[J]. Hepatology, 2012, 55(1):327-328.
[19] Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40(12):1461-1465.
[20] Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2- rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis[J]. Hepatology, 2015, 62(6):1742-1756.
[21] Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease [J]. Gastroenterology, 2010, 138(3):905-912.
[22] Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease[J]. N Engl J Med, 2010, 362(12):1082-1089.
[23] Kozlitina J, Boerwinkle E, Cohen JC, et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance [J]. Hepatology, 2011, 53(2):467-474.
[24] Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis[J]. J Hepatol, 2017, 66(1):123-131.
[25] Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45(4):510-518.
[26] Loomba R, Sanyal AJ. The global NAFLD epidemic[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(11):686-690.
[27] Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies[J]. Hepatobiliary Pancreat Dis Int, 2007, 6(6):572-578.
[28] WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies[J]. Lancet, 2004, 363(9403):157-163.
[29] Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States[J]. Medicine (Baltimore), 2012, 91(6):319-327.
[30] Conus F, Rabasa-Lhoret R, Peronnet F. Characteristics of metabolically obese normal-weight (MONW) subjects[J]. Appl Physiol Nutr Metab, 2007, 32(1):4-12.
[31] Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity[J]. J Hepatol, 2011, 54(6):1244-1249.
[32] Leung JC, Loong TC, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J]. Hepatology, 2017, 65(1):54-64.
[33] Cruz ACD, Bugianesi E, George J, et al. Characteristics and longterm prognosis of lean patients with nonalcoholic fatty liver disease [J]. Gastroenterology, 2014, 146(5):S909.
[34] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60(6):2099-2108.
[35] Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients [J]. J Gastroenterol Hepatol, 2011, 26(9):1361-1367.
[36] Wang MM, Wang GS, Shen F, et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J]. Dig Dis Sci, 2014, 59(10):2571-2579.
[37] Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population[J]. J Hepatol, 2012, 56(3):533-540.
[38] Joo EJ, Chang Y, Yeom JS, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study[J]. Hepatology, 2017, 65(3):828-835.
[39] Jinjuvadia R, Liangpunsakul S. Association between metabolic syndrome and its individual components with viral hepatitis B[J]. Am J Med Sci, 2014, 347(1):23-27.
[40] Kim KH, Shin HJ, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma[J]. Gastroenterology, 2007, 132(5):1955-1967.
[41] Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response[J]. Liver Int, 2017, 34(4):542-551.
[42] Jin X, Chen YP, Yang YD, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J]. PLoS One, 2012, 7(3):e34198.

备注/Memo

备注/Memo:
[基金项目] 国家重点研发计划“ 精准医学研究” (2017YFC0908900)
[通信作者] 范建高, E-mail: fanjiangao@xinhuamed.com.cn
更新日期/Last Update: 2018-03-20